[ABBV] AbbVie Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 62.32 Change: 0.67 (1.08%)
Ext. hours: 62.4 Change: 0.08 (0.13%)

chart ABBV

Refresh chart

Strongest Trends Summary For ABBV

ABBV is in the long-term up 243% in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS4 EPS Growth - 4 Quarters-44.47% EPS Growth - Q/Q-115.9%
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.31% Sales Growth - Q/Q-7.56% P/E17.76
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.8% ROE131.88% ROI11.6%
Current Ratio1.39 Quick Ratio1.3 Long Term Debt/Equity2.45 Debt Ratio8.02
Gross Margin79.12% Operating Margin18.33% Net Profit Margin8.89% Dividend Payout Ratio-154.52%
Dividend Yield
Fundamental Data
Cash From Financing Activities-930 M Cash From Investing Activities-873 M Cash From Operating Activities1.59 B Gross Profit4.58 B
Net Profit1.37 B Operating Profit2.11 B Total Assets26.7 B Total Current Assets15.41 B
Total Current Liabilities11.05 B Total Debt15.27 B Total Liabilities25.32 B Total Revenue5.48 B
Technical Data
High 52 week121.94 Low 52 week64.52 Last close99.98 Last change0.75%
RSI36.24 Average true range2.28 Beta1.14 Volume4.37 M
Simple moving average 20 days-2.68% Simple moving average 50 days2.42% Simple moving average 200 days2.97%
Performance Data
Performance Week-2.94% Performance Month0.35% Performance Quart-11.94% Performance Half6.85%
Performance Year50.73% Performance Year-to-date5.21% Volatility daily1.66% Volatility weekly3.7%
Volatility monthly7.59% Volatility yearly26.29% Relative Volume229.33% Average Volume8.94 M
New High New Low


2019-09-21 17:22:37 | Top Insider Buys Highlight for the Week of Sept. 20

2019-09-21 09:56:16 | Are Insiders Buying AbbVie Inc. NYSE:ABBV Stock?

2019-09-20 13:10:14 | Gilead, AbbVie Are Innovative, but May Be Underappreciated

2019-09-20 07:00:00 | AbbVie Stock Is Falling Because Investors Hate the Allergan Deal. The Vice Chairman Bought Up Shares.

2019-09-19 10:55:02 | The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

2019-09-18 13:30:05 | Top Analyst Reports for AbbVie, Union Pacific & CSX

2019-09-17 16:05:44 | U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers

2019-09-17 11:05:03 | Novartis Announces New Data on Spondylitis Drug Cosentyx

2019-09-16 17:45:09 | AbbVie ABBV Gains As Market Dips: What You Should Know

2019-09-16 09:01:09 | AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's euro notes; stable outlook

2019-09-13 15:29:07 | Dividend Growth ETFs for Long Term Investors

2019-09-13 11:08:03 | Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

2019-09-12 18:22:56 | Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

2019-09-12 17:46:53 | Gilead Tops List of Most Innovative Drug Companies

2019-09-12 16:09:27 | Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade

2019-09-12 11:47:00 | Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says

2019-09-12 10:54:00 | AbbVie Stock Rises After UBS Upgrades To Buy

2019-09-11 09:32:01 | 4 Big Drugmakers Boasting Impressive Oncology Pipelines

2019-09-11 09:15:01 | Why AbbVie ABBV is a Top Dividend Stock for Your Portfolio

2019-09-10 10:55:17 | 10 Healthcare Stocks to Buy Despite the Headlines

2019-09-09 17:45:09 | AbbVie ABBV Dips More Than Broader Markets: What You Should Know

2019-09-09 11:20:03 | The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels

2019-09-08 17:04:41 | Weekly Top Insider Buys Highlight for the Week of Sept. 6

2019-09-08 07:00:00 | 3 Stocks to Buy With Dividends Yielding More Than 6%

2019-09-06 13:56:05 | Top Stock Reports for Microsoft, Home Depot & AbbVie

2019-09-06 10:43:00 | AbbVie Declares Quarterly Dividend

2019-09-05 17:14:05 | Can Copycats Take On $198 Billion In Blockbuster Biotech Sales?

2019-09-05 16:51:07 | 3 Special Situations Gurus Are Buying

2019-09-05 10:18:02 | J&J's Stelara Gets Approval in EU for Ulcerative Colitis

2019-09-04 07:00:00 | 3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T

2019-09-03 14:21:02 | Why Bank of America Says Dividend Stocks are the Only Play Now

2019-09-03 09:21:01 | The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie

2019-09-01 07:30:00 | 3 High-Yield Dividend Stocks to Buy on Sale

2019-08-30 10:21:02 | AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails

2019-08-30 10:11:02 | Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs

2019-08-29 17:18:11 | Big Pharma kills signature drug at center of $5.8 billion South S.F. deal

2019-08-29 09:35:41 | UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T

2019-08-29 09:29:00 | AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

2019-08-29 09:16:00 | AbbVie is shutting down its troubled Rova-T R&D program

2019-08-29 08:59:20 | AbbVie terminates late-stage lung cancer trial

2019-08-29 08:45:00 | AbbVie Discontinues Rovalpituzumab Tesirine Rova-T Research and Development Program

2019-08-28 15:45:05 | UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

2019-08-28 10:15:02 | Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion

2019-08-27 14:03:00 | Should You Buy AbbVie for the Dividend?

2019-08-27 11:36:03 | Lilly's LLY Taltz Gets FDA Nod for Ankylosing Spondylitis

2019-08-27 10:55:02 | Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?

2019-08-27 08:00:00 | AbbVie to Present at the Morgan Stanley Healthcare Conference

2019-08-27 06:00:00 | Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong

2019-08-26 15:40:00 | This dividend-stock strategy is for investors who want an attractive monthly income stream

2019-08-26 10:30:02 | Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study